Investigators from the University of Science and Technology of China and RNAlfa Biotech have described a novel mRNA-based vaccine candidate against Dabie Banda virus (DBV), which has fatality rates of up to 30% in some East Asian countries.
South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes. Detailed in Cell Host & Microbe on Nov. 12, 2025, the database is expected to serve as a universal platform for academia and enable “precision microbiome medicine” for the industry, Lee told BioWorld.
Nkarta Therapeutics Inc. has recently presented data for their allogeneic CAR natural killer (NK) cell therapy, NKX-019, targeting CD19 for treating autoimmune disease through B-cell targeting.
Commit Biologics ApS has released promising results from a nonhuman primate (NHP) study demonstrating proof of concept for its proprietary bispecific complement engager (BiCE) platform.
Inje University has described 3-phosphoinositide-dependent protein kinase 1 (PDPK1) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.
San Francisco Bay Area researchers from UC Berkeley, UC San Francisco and Stanford University have combined their technologies to create Azalea Therapeutics Inc., a company focused on editing cells in vivo.
In Alzheimer’s disease, microglia act as a double-edged sword. They can either protect the brain or worsen the damage, depending on their activation state. Inflammatory activation harms healthy neurons. However, a study reveals that a special type of microglia expressing specific receptors and behaving like T cells may help mitigate this neurodegenerative condition.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged pentacyclic derivatives reported to be useful for the treatment of autoimmune disease.
RSS
